ConductScience.org, home

Comparison · NCT02278718-d3704b8a

NexoBrid Gel vs Standard of Care (SOC): Incidence of Surgical Excision Performed for Eschar Removal

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. NexoBrid Gel vs Standard of Care (SOC): Incidence of Surgical Excision Performed for Eschar Removal. Trial comparisons, record NCT02278718-d3704b8a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02278718-d3704b8a

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.08330.03880.17wilson
Risk in group 20.6440.5290.744wilson
Risk difference, group 1 minus group 2-0.561-0.67-0.417newcombe hybrid score
Risk ratio, group 1 over group 20.1290.0590.284log
Odds ratio, group 1 over group 20.05030.01920.132log
Number needed to treat, for one fewer participant with the outcome on NexoBrid Gel than on Standard of Care (SOC)1.781.492.4from the risk difference interval

Groups2

Group 2 names the comparator: standard of care.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1NexoBrid Gel
NexoBrid Gel is applied to the burn wound at a dose of 2g or 5g NexoBrid sterile powder mixed with 20g or 50g sterile Gel Vehicle per 180cm\^2 of TBSA for four hours.~NexoBrid: NexoBrid is an enzymatic debriding agent for Eschar Removal.
672OG000
Group 2Standard of Care (SOC)Non surgical and Surgical Debridement~Standard of Care: Surgical or Non-Surgical methods for Eschar Removal4773OG001

Outcome

Type
SECONDARY
Title
Incidence of Surgical Excision Performed for Eschar Removal
Description
Number of patients who needed surgical excision for eschar removal
Time frame
Until complete eschar removal has been achieved. Complete eschar removal was achieved within 0.99 days (95% CI: 0.88 to 1.04) for the NexoBrid treatment arm and 5.99 days (95% CI: 2.71 to9.84) for the SOC treatment arm.
Population
Incidence Rate = The proportion and number of patients who required surgical excision for eschar removal.

Source ClinicalTrials.gov

Trial

Title
A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care
NCT number
NCT02278718
Phases
PHASE3
Conditions
Thermal Burns
Interventions
NexoBrid, Standard of Care
Lead sponsor
MediWound Ltd
Results first posted
2024-09-27

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02278718-d3704b8a